Edition:
United States

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.83USD
14 Dec 2017
Change (% chg)

$0.03 (+3.36%)
Prev Close
$0.80
Open
$0.80
Day's High
$0.83
Day's Low
$0.80
Volume
49,576
Avg. Vol
179,652
52-wk High
$5.25
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14
Thursday, 16 Nov 2017 04:45pm EST 

Nov 16 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing.  Full Article

Delmar Pharmaceuticals names Saiid Zarrabian interim CEO
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer.Jeffrey Bacha, cofounder of Co, will continue in role as president and in newly created position of chief operating officer​.Zarrabian and Bacha will continue to serve on company's board of directors​.  Full Article

DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6
Tuesday, 10 Oct 2017 08:15am EDT 

Oct 10 (Reuters) - DelMar Pharmaceuticals Inc :DelMar Pharmaceuticals Inc <<>> CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing.  Full Article

DelMar Pharmaceuticals announces $10 million registered direct offering
Wednesday, 20 Sep 2017 03:31pm EDT 

Sept 20 (Reuters) - DelMar Pharmaceuticals Inc ::Announces $10 million registered direct offering priced at-the-market.Entered into securities purchase agreements of an aggregate of 8 million shares of common stock at $1.25 per share​.  Full Article

Delmar Pharmaceuticals receives IND allowance from FDA
Monday, 18 Sep 2017 08:01am EDT 

Sept 18 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer.  Full Article

Delmar Pharmaceuticals initiates phase 2 clinical trial
Monday, 11 Sep 2017 04:00am EDT 

Sept 11 (Reuters) - Delmar Pharmaceuticals Inc -:Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme.Delmar Pharmaceuticals- clinical trial will explore safety of chemoradiation with VAL-083 as alternative to standard-of-care temozolomide in patients.  Full Article

Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083
Monday, 24 Jul 2017 08:30am EDT 

July 24 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM.Delmar Pharmaceuticals Inc - trial is expected to open for enrollment in coming weeks at Sun Yat-Sen University Cancer Center (SYUCC) in Guangzhou.Delmar Pharmaceuticals Inc - HGRAC approved application to initiate phase 2 safety and efficacy study of its lead product candidate VAL-083.  Full Article

Delmar Pharmaceuticals reports completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory GBM
Tuesday, 18 Jul 2017 08:30am EDT 

July 18 (Reuters) - Delmar Pharmaceuticals Inc ::Delmar Pharmaceuticals announces completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory gbm.Delmar Pharmaceuticals Inc - Delmar anticipates initiation of additional centers and commencement of treatment under star-3 protocol in coming weeks.  Full Article

Delmar Pharmaceuticals appoints Saiid Zarrabian to board
Tuesday, 11 Jul 2017 08:30am EDT 

July 11 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals appoints Saiid Zarrabian to the board of directors and names Erich Mohr as chairman.Delmar Pharmaceuticals Inc - ‍Saiid Zarrabian has joined company's board of directors and Erich Mohr has been elected to serve as its chairman​.  Full Article

DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM
Thursday, 22 Jun 2017 08:30am EDT 

June 22 (Reuters) - DelMar Pharmaceuticals Inc :DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM.DelMar Pharmaceuticals Inc - Remain on track to open enrollment in trial at centers in United States.  Full Article

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage: